IL6R

Chr 1AR

interleukin 6 receptor

Also known as: CD126, HIES5, IL-1Ra, IL-6R, IL-6R-1, IL-6RA, IL6Q, IL6QTL

This gene encodes a subunit of the interleukin 6 (IL6) receptor complex. Interleukin 6 is a potent pleiotropic cytokine that regulates cell growth and differentiation and plays an important role in the immune response. The IL6 receptor is a protein complex consisting of this protein and interleukin 6 signal transducer (IL6ST/GP130/IL6-beta), a receptor subunit also shared by many other cytokines. Dysregulated production of IL6 and this receptor are implicated in the pathogenesis of many diseases, such as multiple myeloma, autoimmune diseases and prostate cancer. Alternatively spliced transcript variants encoding distinct isoforms have been identified in this gene. A pseudogene of this gene is found on chromosome 9. [provided by RefSeq, Aug 2020]

OMIMResearchGenerating clinical summary…
MultiplemechanismARLOEUF 0.813 OMIM phenotypes
Clinical SummaryIL6R
🧬
Gene-Disease Validity (ClinGen)
hyper-IgE recurrent infection syndrome 5, autosomal recessive · ARLimited

Limited evidence — not for standalone diagnostic reporting

Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
1 unique Pathogenic / Likely Pathogenic· 143 VUS of 342 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?
0.81LOEUF
pLI 0.000
Z-score 2.23
OE 0.49 (0.310.81)
Tolerant

Typical tolerance to LoF variation

Missense Constraint?
0.69Z-score
OE missense 0.89 (0.800.98)
254 obs / 286.8 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?
LoF OE?0.49 (0.310.81)
00.351.4
Missense OE?0.89 (0.800.98)
00.61.4
Synonymous OE?1.02
01.21.6
LoF obs/exp: 11 / 22.4Missense obs/exp: 254 / 286.8Syn Z: -0.20

This gene — mechanism propensity

DN
0.74top 25%
GOF
0.73top 25%
LOF
0.2871th %ile

This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative and gain-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to dominant-negative as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

DNprediction above median
GOFprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

342 submitted variants in ClinVar

Classification Summary

Pathogenic1
VUS143
Likely Benign162
Benign22
Conflicting1
1
Pathogenic
143
VUS
162
Likely Benign
22
Benign
1
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
1
0
0
1
Likely Pathogenic
0
0
0
0
0
VUS
7
124
9
3
143
Likely Benign
0
9
60
93
162
Benign
0
0
15
7
22
Conflicting
1
Total713484103329

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

15 pathogenic / likely-pathogenic (of 22) ClinVar copy-number / structural variants overlap IL6R — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

IL6R · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Anterior Cruciate Ligament Injuries

Biologic Therapy to Prevent Osteoarthritis After ACL Injury

RECRUITING
NCT03968913Phase EARLY_PHASE1University of California, Los AngelesStarted 2021-09-15
Anakinra injectionsterile saline injection
Porphyria, Acute Intermittent

Clinical Research on Acute Intermittent Porphyria and the Use of Carbohydrate-Rich Diet as a Treatment

RECRUITING
NCT06273644Phase NANordlandssykehuset HFStarted 2024-01-27
Carbohydrates
Type 2 DiabetesInflammationInsulin Sensitivity/Resistance

Targeting Risk Factors for Diabetes in Subjects With Normal Blood Cholesterol Using Omega-3 Fatty Acids

RECRUITING
NCT04485871Phase NAInstitut de Recherches Cliniques de MontrealStarted 2019-12-19
Omega-3 fatty acids
Endometriosis

Developing a Complex ex Vivo Endometrial Tissue Model to Improve Endometriosis Care

RECRUITING
NCT06331676Phase NAHospices Civils de LyonStarted 2024-06-21
Tissue collectionData collection
Glioma of Brain

Glioma Microenvironment an Exploratory Study

ACTIVE NOT RECRUITING
NCT03189420Hospital Sirio-LibanesStarted 2016-10
Tumor resection
Facioscapulohumeral Muscular Dystrophy 1

Study to Evaluate the Efficacy and Safety of Satralizumab in FSHD1

ACTIVE NOT RECRUITING
NCT06222827Phase PHASE2Centre Hospitalier Universitaire de NiceStarted 2024-01-24
Satralizumab Prefilled SyringePlacebo Comparator
Osteoarthritis, KneeOsteo Arthritis KneeKnee Osteoarthritis

Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis

ACTIVE NOT RECRUITING
NCT05835895Phase PHASE1Genascence CorporationStarted 2023-06-12
GNSC-001transient immune-modulationtransient immune-modulation
Hand OsteoarthritisErosive Osteoarthritis

Methotrexate in Erosive Inflammatory Hand Osteoarthritis

ACTIVE NOT RECRUITING
NCT04579848Phase PHASE4Diakonhjemmet HospitalStarted 2021-08-12
Methotrexate TabletsPlaceboFolic Acid 1 MG
Chronic Post Operative Pain

Cytokine Alterations and Chronic Post-Surgical Pain

NOT YET RECRUITING
NCT06418295London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sStarted 2026-01-01
Unilateral thoracotomy
Healthy

Pulmonary Immune Cell-microbiome Interactions in the Healthy Lung

RECRUITING
NCT05846620Hvidovre University HospitalStarted 2023-04-17
Bronchoalveolar lavage
Coronary Heart Disease

Adipose Tissue and Inflammation in Coronary Heart Disease

ACTIVE NOT RECRUITING
NCT02760914Oslo University HospitalStarted 2016-06
Osteoarthritis, Knee

Study to Evaluate the Safety and Tolerability of FX201 in Patients with Osteoarthritis of the Knee

ACTIVE NOT RECRUITING
NCT04119687Phase PHASE1Pacira Pharmaceuticals, IncStarted 2020-03-02
FX201